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Abstract Although most meningiomas are encapsulated
and benign tumors with limited numbers of genetic aber-
rations, their intracranial location often leads to serious and
potentially lethal consequences. They are the most fre-
quently diagnosed primary brain tumor accounting for
33.8% of all primary brain and central nervous system
tumors reported in the United States between 2002 and
2006. Inherited susceptibility to meningioma is suggested
both by family history and candidate gene studies in DNA
repair genes. People with certain mutations in the neuro-
ﬁbromatosis gene (NF2) have a very substantial increased
risk for meningioma. High dose ionizing radiation expo-
sure is an established risk factor for meningioma, and lower
doses may also increase risk, but which types and doses are
controversial or understudied. Because women are twice as
likely as men to develop meningiomas and these tumors
harbor hormone receptors, an etiologic role for hormones
(both endogenous and exogenous) has been hypothesized.
The extent to which immunologic factors inﬂuence
meningioma etiology has been largely unexplored. Grow-
ing emphasis on brain tumor research coupled with the
advent of new genetic and molecular epidemiologic tools
in genetic and molecular epidemiology promise hope for
advancing knowledge about the causes of intra-cranial
meningioma. In this review, we highlight current knowl-
edge about meningioma epidemiology and etiology and
suggest future research directions.
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Epidemiologic research on meningioma
Compared to the malignant glial tumors, meningiomas are
relativelyunderstudied with regards toetiologic riskfactors.
The challenges to meningioma research are several: (i) as a
relatively rare disease, large or multicenter studies are nec-
essary for sufﬁcient numbers; (ii) the long latency of
meningioma of 20–30 years or more, exhibited most evi-
dentially in studies with known doses of ionizing radiation
[1], makes exposure ascertainment difﬁcult due to recall
bias; (iii) the prevalence of subclinical disease in up to 2.8%
of the population, as suggested by autopsy studies [2, 3],
indicatesthatthepoolofsusceptiblepersonsaremuchlarger
than those with clinically conﬁrmed diagnoses; and (iv) the
problem of detection bias—many meningiomas are discov-
ered incidentally via MRIs for conditions such as head
trauma or sinus problems. These incidentally discovered
meningiomas, and a signiﬁcant portion of primarily dis-
covered meningiomas are managed ‘‘conservatively,’’
meaning by observation and not surgical removal. One way
epidemiologists can minimize detection bias is to only
ascertain cases who have undergone surgical removal and
J. Wiemels (&)
Department of Epidemiology and Biostatistics, University
of California San Francisco, Helen Diller Cancer Research
Building, 1450 3rd Street, MC 0520, San Francisco,
CA 94158, USA
e-mail: joe.wiemels@ucsf.edu
M. Wrensch
Department of Neurological Surgery, Epidemiology
and Biostatistics, University of California San Francisco,
San Francisco, CA, USA
E. B. Claus
Department of Epidemiology and Public Health, Yale University
School of Medicine, New Haven, CT, USA
E. B. Claus
Brigham and Women’s Hospital, Boston, MA, USA
123
J Neurooncol (2010) 99:307–314
DOI 10.1007/s11060-010-0386-3pathological conﬁrmation, ensuring that cases have clini-
cally-signiﬁcant meningioma. Only a few epidemiologic
studies of intracranial tumors to date have been adequately
powered to study separately risk factors for meningioma.
These include the large European cohorts such as the Inter-
phone [4], and the Million Women Study in the United
Kingdom [5]. Several large European country- or region-
speciﬁc case–control studies were spawned from the Inter-
phonestudy[6–8].In2002,TheBenignBrainTumorCancer
Registries Amendment Act (H.R. 5204) was passed, man-
dating registration of benign brain tumors such as meningi-
oma in the United States. This legislation has and will
continue to enhance reporting of both incidence rates and
survivaltimesforpatientswithmeningioma.Beforethisact,
meningioma mortality rate estimates were hampered by
incomplete reporting and potential selection biases with
respect to the individuals who were included in the data-
bases, as well as limited follow-up information. The better
qualityofnewinformationaffordsexceptionalopportunities
totheresearchandclinicalcommunitiesinthecomingyears.
Population statistics
The prevalence of pathologically-conﬁrmed meningioma is
estimated to be approximately 97.5/100,000 in the United
States with over 170,000 individuals currently diagnosed
with this tumor [9]. Since a proportion of meningiomas are
not surgically managed, these estimates are low. In addi-
tion, autopsy and imaging studies have estimated subclin-
ical meningioma rates of up to 2.8% in women [2, 3]. Data
from the Central Brain Tumor Registry of the United States
(CBTRUS) demonstrates a more than twofold higher
incidence among females [age-adjusted incidence rate (per
100,000 person years) of 8.36 and 3.61 for females and
males, respectively] [9]. The female:male ratio of
approximately 2:1 may be inverted for rare pre-pubertal
meningiomas [10, 11]. Atypical and malignant meningio-
mas comprise a small fraction of the total (*5%) and have
a slight male predominance. Reported rates for Black Non-
Hispanics are slightly higher (6.67) than for White Non-
Hispanic and Hispanics (5.90 and 5.94, respectively) [9].
Age-speciﬁc incidence rates (Fig. 1) reveal increasing risk
with age in both men and women. Increasing risk of
meningioma over the past several decades noted in
CBTRUS [9] may be an artifact of increasingly accurate
reporting of this disease.
Molecular etiology
Meningioma cells exhibit a striking similarity to arachnoid
cap cells, which are the likely tumor cell of origin. Despite
the fact that meningioma has a benign pathophysiology in
95% of cases, like carcinoma it always results from a clonal
outgrowth derived from a single cell as exempliﬁed by
cytogenetic and array-comparative genomic hybridization
(array-CGH) studies [12, 13]. Sporadic meningiomas are
typically associated with one or more focal chromosomal
deletion(s), and atypical and malignant grades tend to have
multiple chromosomal copy number alterations consistent
with the acquisition of ‘‘mutator’’ mutations which foster
genomic instability [14]. Deletion and inactivation of NF2
on chromosome 22 is a predominant feature in sporadic
meningiomas, and biallelic deletions are common [13].
Additional genes are likely involved as well, since loss of
NF2 occurs in only 1/3 of patients who exhibit loss of
heterozygosity of chromosome 22 [15]. Additional genomic
regions which are recurrently lost in meningiomas include
14q, 1p, 6q, and 18q [16]. Although in one study, familial
meningiomas did not demonstrate inherited copy number
alterations, such families typically have a germline defect in
NF2 or other predispositing mutations [14]. Indeed,
meningiomas are reported in families of several cancer
predisposition syndromes including those involving the
genes NF1, PTCH, CREBBP, VHL, PTEN, and CDKN2A
(reviewed in [17]). Epigenetic aberrations in meningioma
have not been thoroughly assessed, but one study suggests
that DNA methylation events may impact meningioma
biology more signiﬁcantly than DNA copy number muta-
tions [18]. Clearly, complexity of genetic aberrations in
meningioma increases with tumor grade [19]. A relatively
small number of mutations may be necessary for most
meningiomas; however their slow growth makes long
latency an issue, lending difﬁculty in identifying the source
and timing of the initiating mutations, presenting a further
complication for epidemiology studies.
Fig. 1 Age and gender-speciﬁc incidence rates (per 100,000 popu-
lation) for meningioma in the United States (2002–2006) (from
reference 4). The left Y-axis scale refers to the bar graphs. The ratio
of female to male incidence is indicated by a diamond at each age
group, and the axis for the ratio is along the right hand side of the
ﬁgure. The peak ratio of 3.15, female:male, is among the 35–44 year
age group
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Ionizing radiation
At present, the primary environmental risk factor identiﬁed
for meningioma is exposure to ionizing radiation (IR) with
risks from six fold to ten fold reported [20–23]. At high
dose levels, data exist for atomic bomb survivors showing a
greatly increased risk for meningioma [21]. Evidence also
exists for lower dose levels. In one of the most well-known
studies of ionizing radiation and meningioma risk, children
who were given radiation therapy for scalp ringworm in
Israel between 1948 and 1960 (the Tinea Capitis Cohort),
were observed to have a relative risk of almost 10 for
meningioma [24]. A number of studies have linked the
number of full-mouth dental radiographs to risk of
meningioma (reviewed in [25]) although the sample sizes
are limited and some subsequent studies (also small in size)
did not replicate earlier studies [26, 27]. However, the most
recent case/control study of 200 meningioma patients
reported that patients reporting full-mouth X-rays had a
signiﬁcantly increased risk of meningioma (OR 2.06, 95%
CI 1.03, 4.17) although evidence for a dose response
relation was lacking (P for trend = 0.33) [28]. Radiation
therapy for intra-cranial tumors has also been linked to
meningioma risk [22]. No recent large-scale studies of
meningioma risk relative to ionizing radiation exist. Such
studies are still highly relevant in the current era in which
X-ray doses for dental and other procedures have
decreased, since new radiographic procedures with signif-
icant exposure risks have been introduced, including
computed tomography (CT).
Hormones
An association between hormones and meningioma risk
has been suggested by a number of ﬁndings including the
increased incidence of post-pubertal disease in women
versus men (2:1) with the highest ratio of 3.15:1 during the
peak reproductive years (Fig. 1), the presence of estrogen,
progesterone, and androgen receptors on some meningio-
mas, an association between breast cancer and meningio-
mas (see below), indications that meningiomas change in
size during the luteal phase of the menstrual cycle and
pregnancy, and the regression of multiple meningiomas in
a patient following cessation of estrogen agonist therapy
[29, 30]. Despite these sentinel clues, meningioma is far
from exhibiting a ‘‘hormone-fed’’ character in the clinic
and epidemiologic measures of endogenous and exogenous
hormones are not consistently associated with meningioma
incidence.
Researchers have only begun to address the question of
whether the use of exogenous hormones such as oral
contraceptives (OC) and/or hormone replacement therapy
(HRT) is associated with an increased risk of meningioma
[5, 29, 31–35]. Data from two cohort studies and several
case/control studies exist. In a case/control study nested
within the Nurse’s Health Study (NHS) (including 125
cases of meningioma), the relative risk of meningioma
associated with hormone use for pre-menopausal women
was 2.48 (95% CI 1.29, 4.77) when compared with post-
menopausal women who had never used hormones [34].
For postmenopausal women who were hormone users the
relative risk was 1.86 (95% CI 1.07, 3.24). No excess risk
was associated with past hormone use. No association was
found for past or current use of oral contraceptives.
Recently published data from a cohort study of 1.3 million
women with a mean age of 55.9 and recruited from 1996 to
2001 (The Million Women Study) did not ﬁnd an associ-
ation between OC use (OR 1.06, 95% CI 0.81–1.38 for use
within the past ﬁve years) and meningioma risk (n = 390)
but did not report results for HRT use [5]. In a large and
recent case/control study, the Interphone Group reported an
increased relative risk of meningioma (n = 178) among
postmenopausal women for ever-use of HRT (OR 1.7, 95%
CI 1.0–2.8) [35]. Women who had used long-acting hor-
monal contraceptives also had an increased risk of
meningioma; the odds ratio for at least 10 years of use was
2.7 (95% CI 0.9–7.5). A retrospective records-based cohort
study using the Mayo Clinic Jacksonville patient database
between 1993 and 2003 conﬁrms the positive NHS ﬁndings
(OR 2.2, 95% CI 1.9–2.6) of an association between HRT
use and meningioma risk, comparing the frequency of HRT
use among a case population of 1,390 with over 350,000
other women in the health system [31], while a case/control
study including 219 meningioma cases identiﬁed from
three Chicago area hospitals between 1987 and 1992
reports a protective effect for oral contraceptive use (OR
0.2, 95% CI 0.0–0.8) and a non-statistically signiﬁcant
protective effect associated with HRT use [32]. This latter
study used the spouses of men with back pain as controls.
Hence at present, there is limited statistical evidence of an
increased risk of meningioma among users of oral contra-
ceptives. Although not deﬁnitive, available data suggest an
association between the use of hormone replacement
therapy and increased meningioma risk. Further evaluation
of exogenous hormone use in women with meningioma in
a larger study is needed with particular attention to strati-
ﬁcation by hormone composition (i.e. estrogen and/or
progesterone), duration of and age at use as well as
meningioma subgroups deﬁned by tumor receptor expres-
sion (see below).
Researchers have also reported conﬂicting results when
examining meningioma risk across categories of preg-
nancy, menstrual and anthropometric variables [5, 29, 31–
36]. When examining age at ﬁrst menstrual period,
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tive risk for meningioma for women with age at menarche
12–14 years of 1.29 (95% CI 0.86–1.92) and for women
with age at menarche after 14 years a relative risk of 1.97
(95% CI 1.06–3.66) compared to those with menarche
before age 12 [34]. A tendency for increased risk of
meningioma for parous compared to non-parous women
(RR = 2.39, 95% CI 0.76–7.53) was also observed,
although this value was not statistically signiﬁcant [34]. In
a second nested case/control study, Lambe et al. examined
1088 patients with meningioma within the Swedish Cancer
Registry and matched to data from the Swedish Fertility
Registry [36]. This group found no association between
either parity or age at ﬁrst birth and meningioma risk,
however their analyses were not adjusted for other possible
meningioma risk factors such as use of exogenous hor-
mones or radiation exposure history. Data from the Inter-
phone Study suggest that meningioma risk among women
aged\50 years is increased with increasing number of
livebirths (OR 1.8, 95% CI 1.1–2.8 for three versus no
livebirths) but found no association with menopausal status
[35]. The Million Women Cohort reported an increasing
risk of meningioma with increasing body mass index (OR
1.46, 95% CI 1.11–1.91) but no association with number of
pregnancies or age at ﬁrst birth [5]. Body mass index, or
more speciﬁcally body fat, is positively associated with
aromatase activity resulting in higher endogenous estrogen
exposure. An additional case/control study which included
219 cases found a protective effect for pregnancy which
increased with number of pregnancies and age at ﬁrst
pregnancy [32]. Neither age at menarche or menopause
were reported to show any effect in unadjusted analyses
although menopause showed an increased risk (OR 2.0,
95% CI 1.0–4.0) in adjusted analyses. In summary, the
association between traditional hormone-based pregnancy
and menstrual risk factors and meningioma risk is not
consistent and deserve a more formal examination. Such an
examination requires precise exposure assessments as well
as an incorporation of a more thorough examination of
biological features of individual patients data, including the
expression of hormone receptors as described below, which
may reveal subtypes with more clear evidence of hormone
associations.
The functional signiﬁcance of hormone receptors expres-
sed on meningiomas is still controversial. Hormone receptors
(estrogen, progesterone, and androgen) are expressed in an
equivalent proportion of meningiomas derived from men and
women [37], but their assessment has only been performed
once in an epidemiologic study [38], and different laboratory
methods for receptor expression capture widely varying
proportions of positive patients [39–41]. A pilot study of 31
meningioma samples reported that a speciﬁc gene expression
pattern appeared more strongly associated with PR status
than with ER status [42]. Genes on the long arm of chro-
mosome 22 and near the NF2 gene (22q12) were most fre-
quently noted to have expression variation, with signiﬁcant
up-regulation in PR positive versus PR negative lesions
suggesting a higher rate of 22q loss in PR negative lesions.
Pathway analyses indicated that genes in collagen and
extracellular matrix pathways were most likely to be differ-
entially expressed by PR status [42]. The future incorporation
of receptor expression into epidemiology studies may revo-
lutionize the ﬁeld as various molecular markers have done
for cancers, for example hormone receptors in breast cancer.
The ﬁeld ﬁrst needs to harmonize methodology to classify
hormone receptors so that different studies can be compared
and contrasted.
Head trauma
Head trauma has been suggested as a risk factor for
meningioma since the time of Harvey Cushing, although
the results across studies are not consistent. While some
small case/control studies report an increased risk of
meningioma associated with head trauma for both males
and females [43, 44], other studies report no such associ-
ation [45, 46]. In a cohort study of 228,055 Danish resi-
dents hospitalized for concussion, skull fracture or other
head injury between 1977 and 1992 and followed for an
average of eight years, the standardized incidence ratio
(SIR) for meningioma after the ﬁrst year was 1.2 (95%CI
0.8, 1.7) [47]. As mentioned above, associations of head
trauma and meningioma may be an example of detection
bias.
Cell phone use
The question of whether cell phone use is related to
meningioma risk remains a question of great interest to the
general public. At least ten studies have examined the
association between cell phone use and tumors of the brain.
At present, little evidence exists for an association between
the two although sample sizes speciﬁc to meningiomas are
relatively small, the follow-up time since commencement
of cell-phone use is relatively short, and, in some instances,
the measurement of cell-phone use is somewhat crude
[48–50]. Newly reported data from the large Interphone
study may also suffer some reporting bias; this study repli-
cated earlier negative ﬁndings even for the highest exposed
groups ([10 years of heavy exposure) [4]. If the latency
times of 17–36 years observed in ionizing radiation studies
on the epidemiology of meningioma [24, 51] are taken as a
guideline, the true extent of any possible relationship
between cell phone use and meningioma risk may not be
uncovered for decades and therefore this topic deserves
continued attention.
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An association between breast cancer and meningioma has
been examined in several studies [29, 52, 53]. A number of
explanations have been proposed for this association
including the presence of common risk factors such as
endogenous and exogenous hormones as well as shared
genetic predisposition, including variants in DNA repair
polymorphisms [52]. A review of the literature as well as
an analysis of the association between breast cancer and
meningioma using the western Washington State cancer
registry data was provided by Custer et al. [53]. The rela-
tive risks observed across existing studies range between
1.5 and 2.0 with the majority statistically signiﬁcant. Most
of these studies have been conducted with tumor registry
data and have relatively small sample sizes and none have
been able to examine the association while controlling for
risk factors which are likely to be shared by the two
tumors, such as pregnancy and menstrual variables and
exogenous hormone use. The fact that studies which
identify risk of breast cancer in women who had menin-
gioma, and vice versa, both have similar magnitude
increased risk suggests that there is not a causal relation-
ship between these tumors, rather that they share the same
risk factors such as gender, age, hormone induction, and
possibly other demographic variables [53].
Occupation/diet/allergy
Attempts to link speciﬁc chemicals with meningiomas in
occupationally or industrially exposed groups have proved
inconclusive (reviewed in [54]). An international case/
control study found no association between diet and
meningioma (n = 332) [55]. Although a number of studies
which examine the relationship between glial brain tumors
and allergic disease such as asthma and eczema have found
evidence for an association, little evidence has been found
for such an association for meningioma [6, 8, 56]. A meta-
analysis however demonstrated a signiﬁcant inverse rela-
tionship of meningioma with allergy when excluding the
single study that was most heterogeneous from the others
(pooled RR = 0.84, 95% CI 0.72–0.98, P = 0.029) [57],
and a large recent study showed consistent inverse risk
with asthma, hayfever, and eczema [7]. A study of innate
immune genes did not ﬁnd strong evidence of risk imparted
by variants in such genes, but more investigation is war-
ranted [58].
Family history of meningioma
Few studies have examined the relationship between
meningioma risk and family history of meningioma.
Malmer et al. examined cancer risk in spouses and ﬁrst
degree relatives of brain tumor patients in Sweden and
reported that a meningioma diagnosis conferred a two fold
increase in meningioma risk to ﬁrst degree relatives
(standardized incidence ratio [SIR] 2.2, 95% CI 1.4, 3.1)
but not to spouses of affected individuals [59]. An inverse
association between risk and age at onset was observed
with an SIR of 2.5 (95% CI 1.5–4.0) for probands less than
50 years of age versus 1.3 (95% CI 0.6–2.6) for probands
older than 50 years of age. Similar analyses by Hemminki
et al. using data from the Swedish and Norweigian Registry
Databases, reveal an increased risk with increasing num-
bers of affected ﬁrst degree relatives with persons having
one or two ﬁrst degree family members with meningioma
(SIR 1.6, 95% CI 1.3–42.0, and SIR 5.0, 95% CI 0.9–14.8),
respectively [60]. Despite the fact that up to one to three
percent of the adult population may harbor a meningioma
[2, 3], the total number of families with multiple members
diagnosed with meningioma are relatively rare (indicating,
in part, a wide spectrum of phenotypic expression with
respect to clinical import and hence screening undertaken),
and most such families are currently attributed to inherited
NF2 mutations. At present no family based linkage or
segregation analyses studies of meningioma have been
reported.
Molecular epidemiology
In the most recent and largest study to date of genetic poly-
morphisms and meningioma risk, Interphone study investi-
gators reported a statistically signiﬁcant association with
meningioma for 12 SNPs drawn from DNA repair genes
[52]. These investigators examined 1,127 tagging SNPs
selected to capture most of the common variation in 136
DNA repair genes as well as an additional 388 putative
functional SNPs. These included69 nonsynonymous coding
SNPs that may identify functional changes in expressed
proteins. A total of 631 cases and 637 controls drawn from
ﬁve case/control series from the Interphone Study were
genotyped. The Interphone study is a case/control project
initially designed to examine the relationship between cell
phone use and the risk of brain tumors, including meningi-
oma. Study subjects are primarily Western European back-
ground. The group reported a novel and biologically
intriguing association between meningioma risk and three
variants in the gene that encodes breast cancer susceptibility
gene 1-interacting protein 1 (BRIP1) (17q22). The most
signiﬁcant was SNP rs4968451 that maps to intron 4 of the
gene (OR 1.61, 95% CI 1.26–2.06 heterozygotes, OR 2.33,
95% CI 1.25–4.34 homozygotes). The BRIP1 gene is
involved in the repair of DNA double-strand breaks by
homologous recombination in a manner that depends on its
association with BRCA1. Defects in BRIP1 are linked to
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leadingresearcherstospeculatethatthereportedassociation
between breast cancer and meningioma risk may be due to
similardefectsinDNArepairgenesratherthan/inadditionto
thepreviouslyassumedsharedhormonalriskfactors(suchas
hormone replacement therapy). This group also reported a
statistically signiﬁcant association between four variants in
the ATM gene, a member of the phosphatidylinositol-3
kinasefamilyknowntobeinvolvedinhomologousandnon-
homologous DNA break repair, and meningioma risk. Pre-
vious groups have also noted signiﬁcant associations
between ATM variants for meningioma as well as breast
cancer[23,61].Theseﬁndingsareagainofinterestinlightof
theassociationsbetweenionizingradiationandmeningioma
risk as well as between breast cancer and meningioma risk.
Additional candidate genes studies have suggested a role
for genes in apoptotic pathways [62], and as discussed
above, immune regulatory pathways [58] and meningioma
risk. Earlier studies examined variants in phase II metabolic
genes, which would impact response to environmental or
occupational chemical exposures; a meta-analysis of these
studies implicates a potential role for the detoxifying
enzyme GSTT1 in modulating meningioma risk
(OR = 1.95, 95% CI 1.02–3.79) [63]. The lack of replica-
tion/conﬁrmation and low number of variants assessed in
candidate genes studies distracts from knowledge on the
true genetic susceptibility of meningioma, which awaits
results from agnostic genome-wide association studies.
Directions for future studies
Because of its ‘‘benign’’ nature, research in meningioma
epidemiology and etiology has lagged behind that for more
malignant intracranial neoplasms. The study of risk factors
for meningioma remains challenging, and there are cur-
rently few large-scale studies. The two main known risk
factors—genetic predisposition and high dose radiation
exposures—account for a small proportion of cases.
Although a role for hormones is possible given the gender
distributionofmeningiomas,littlespeciﬁcorconsistentdata
exist on hormonal risk factors. Epidemiologic tools may be
used to collect and deﬁne appropriate subject data from
well-characterized source populations, being mindful of
detection or diagnostic bias in patient ascertainment, in an
effort to delineate risk factors both for the overall group of
meningioma patients as well as for speciﬁc subgroups. High
quality follow-up data for sufﬁcient time periods must be
collected on meningioma patients to obtain representative
estimates of sex- and age-speciﬁc rates for recurrence,
quality of life and overall survival. In addition to the col-
lection of data on environmental risk factors such as hor-
moneuse,newprojectswillneedtoconsidertheinclusionof
information on relevant genetic variants derived from
ongoing whole genome and gene pathway scans. In addition
to exploring environmental and genetic factors for menin-
gioma risk separately, the interaction between the two must
be examined. For example, the integration of environmental
risk factors such as oral contraceptive use or radiation
exposure with information on genetic polymorphisms in
steroid hormone or DNA repair genes may help researchers
to understand the complex relationship between genetic
susceptibility and environmental exposures in the develop-
ment of meningioma. Given the large numbers of subjects
needed to study such gene-environment interactions, espe-
cially within deﬁned subsets of meningioma such as the rare
atypical and malignant subtypes, collaborative, multi-center
efforts between a variety of researchers will be needed,
including experts from such ﬁelds as neurosurgery, epide-
miology, genetics, statistics, and neuropathology.
Meningioma epidemiology and etiology will beneﬁt
from the increased size and quality of disease reporting to
cancer registries, facilitated in the USA by the Benign Brain
Tumors Act of 2002. This act has resulted in the formation
of a multicenter meningioma consortium, which is matched
by several large studies in Europe. These studies will
facilitate a rapid and thorough investigation into the genetic
susceptibility factors for meningioma via genome-wide
association and whole genome sequencing in the near
future. The collection of blood and tumor material must
accompany such studies to facilitate the rational classiﬁ-
cation of the disease into etiologic subtypes to further
specify genetic, immunologic, and environmental risk fac-
tors. Exposure assessments will continue to hinder progress
in meningioma case–control studies, which are hampered
by information bias because of poor or differential recall by
study subjects, and the lack of veriﬁable biomarkers of
exposure since information is obtained in retrospect. Future
large cohort studies may help to ameliorate this problem,
and large linked health databases may help study iatrogenic
risk factors such as diagnostic and therapeutic ionizing
radiation, and therapeutic hormone use.
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